Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Phase 3 save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
Published: 2022-07-13 (Crawled : 21:00) - biospace.com/
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: -3.58%
H: 10.41%
C: 5.76%
study phase 3
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
Published: 2022-07-12 (Crawled : 12:00) - biospace.com/
BLU | $14.74 0.03% 0
|
Health Technology
|
| O: -9.67%
H: 2.37%
C: -0.41%
blu-5937 fda meeting health program positive phase 3 phase 2
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -8.91%
zynlonta biopharma trial china phase 3
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.94%
H: 1.28%
C: -0.35%
treatment rare disease kidney study phase 3
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $38.72 -2.25% -0.28% 970K
|
Health Technology
|
| O: -0.11%
H: 0.14%
C: -0.17%
trial phase 3
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
ANVS | $12.74 7.24% -2.04% 490K
|
Health Technology
|
| O: 11.24%
H: 7.12%
C: 1.69%
fda disease trial positive buntanetap anvs401 posiphen phase 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
takhzyro children trial positive results phase 3
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseasePhase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.34%
H: 10.15%
C: 8.54%
gbt601 trial phase 3
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - biospace.com/
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.78%
H: 1.49%
C: -0.15%
trial results sclerosis phase 3 topline
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.78%
H: 1.49%
C: -0.15%
trial results sclerosis phase 3 topline
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
Published: 2022-06-27 (Crawled : 13:20) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.64%
H: 29.84%
C: 15.32%
treatment trial therapeutics phase 3
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
Published: 2022-06-27 (Crawled : 13:20) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 9.24%
H: 0.0%
C: -5.38%
trial phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: -1.36%
H: 2.53%
C: 0.0%
trials therapeutics presentation sclerosis phase 3
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis
Published: 2022-06-23 (Crawled : 14:00) - biospace.com/
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 0.7%
H: 1.66%
C: -2.72%
tmb-001 trial phase 3
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
Published: 2022-06-22 (Crawled : 13:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K
|
Health Technology
|
| O: 5.37%
H: 1.85%
C: -5.56%
ph94 treatment social anxiety disorder phase 3
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M
|
Health Technology
|
| O: -53.55%
H: 0.0%
C: 0.0%
biopharma disease trial phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.